Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2 Spike-specific IFN-γ T-cell Response After COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant.
Imhof C, Messchendorp AL, van der Heiden M, Baan CC, van der Molen RG, Remmerswaal EBM, de Vries RD, Diavatopoulos DA, Boerma A, Bakker FJ, Oosterhout E, Bemelman FJ, Hilbrands LB, Reinders MEJ, Gansevoort RT, Sanders JS, van Baarle D. Imhof C, et al. Among authors: boerma a. Transplant Direct. 2022 Oct 18;8(11):e1387. doi: 10.1097/TXD.0000000000001387. eCollection 2022 Nov. Transplant Direct. 2022. PMID: 36284929 Free PMC article.
Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours.
Oosting SF, van der Veldt AAM, Fehrmann RSN, GeurtsvanKessel CH, van Binnendijk RS, Dingemans AC, Smit EF, Hiltermann TJN, den Hartog G, Jalving M, Westphal TT, Bhattacharya A, de Wilt F, Boerma A, van Zijl L, Rimmelzwaan GF, Kvistborg P, van Els CACM, Rots NY, van Baarle D, Haanen JBAG, de Vries EGE. Oosting SF, et al. Among authors: boerma a. Lancet Oncol. 2022 Jul;23(7):833-835. doi: 10.1016/S1470-2045(22)00203-0. Epub 2022 Apr 25. Lancet Oncol. 2022. PMID: 35483383 Free PMC article. No abstract available.
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
Tan NH, Geers D, Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Bogers S, van Dijk LLA, Gommers L, van Leeuwen LPM, Boerma A, Nijhof SH, van Dort KA, Koopmans MPG, Dalm VASH, Lafeber M, Kootstra NA, Huckriede ALW, van Baarle D, Zaeck LM, GeurtsvanKessel CH, de Vries RD, van der Kuy PHM; SWITCH ON Research Group. Tan NH, et al. Among authors: boerma a. Lancet Infect Dis. 2023 Aug;23(8):901-913. doi: 10.1016/S1473-3099(23)00140-8. Epub 2023 Apr 21. Lancet Infect Dis. 2023. PMID: 37088096 Free PMC article. Clinical Trial.
Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors.
Oosting SF, van der Veldt AAM, Fehrmann RSN, Bhattacharya A, van Binnendijk RS, GeurtsvanKessel CH, Dingemans AC, Smit EF, Hiltermann TJN, den Hartog G, Jalving M, Westphal TT, de Wilt F, Ernst SM, Boerma A, van Zijl L, Rimmelzwaan GF, Kvistborg P, van Els CACM, Rots NY, van Baarle D, Haanen JBAG, de Vries EGE. Oosting SF, et al. Among authors: boerma a. ESMO Open. 2023 Aug;8(4):101599. doi: 10.1016/j.esmoop.2023.101599. Epub 2023 Jun 21. ESMO Open. 2023. PMID: 37450950 Free PMC article. No abstract available.
One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment.
van der Veldt AAM, Oosting SF, Fehrmann RSN, GeurtsvanKessel CH, van Binnendijk RS, Dingemans AC, Smit EF, Hiltermann TJN, Hartog GD, Jalving M, Westphal TT, Bhattacharya A, de Wilt F, Ernst SM, Boerma A, van Zijl L, Rimmelzwaan GF, Kvistborg P, van Els CACM, Rots NY, van Baarle D, Haanen JBAG, de Vries EGE. van der Veldt AAM, et al. Among authors: boerma a. ESMO Open. 2023 Feb;8(1):100785. doi: 10.1016/j.esmoop.2023.100785. Epub 2023 Jan 10. ESMO Open. 2023. PMID: 36764094 Free PMC article. No abstract available.
First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers.
Komdeur FL, Singh A, van de Wall S, Meulenberg JJM, Boerma A, Hoogeboom BN, Paijens ST, Oyarce C, de Bruyn M, Schuuring E, Regts J, Marra R, Werner N, Sluis J, van der Zee AGJ, Wilschut JC, Allersma DP, van Zanten CJ, Kosterink JGW, Jorritsma-Smit A, Yigit R, Nijman HW, Daemen T. Komdeur FL, et al. Among authors: boerma a. Mol Ther. 2021 Feb 3;29(2):611-625. doi: 10.1016/j.ymthe.2020.11.002. Epub 2020 Nov 5. Mol Ther. 2021. PMID: 33160073 Free PMC article. Clinical Trial.
19 results